Agenus sees wobbly gain on Phase II glioblastoma data
This article was originally published in Scrip
Executive Summary
Agenus gained as much as 34.3% before its stock closed 10.2% higher on 17 September following the announcement of what appear to be impressive survival data for its cancer vaccine HSPPC-96 in the treatment of newly-diagnosed glioblastoma multiforme (GBM).